AbbVie: FDA to Review Atogepant for Preventive Treatment of Migraine
March 30 2021 - 8:50AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. on Tuesday said the U.S. Food and Drug
Administration accepted its new drug application for atogepant for
the preventive treatment of migraine in adults who meet criteria
for episodic migraine.
The North Chicago, Ill., biopharmaceutical company said it
expects a decision from the agency late in the third quarter.
AbbVie said atogepant, if approved, would be the first and only
oral calcitonin gene-related peptide receptor antagonist
specifically developed for the preventive treatment of
migraine.
AbbVie already markets Botox as a preventive treatment for
chronic migraine and Ubrelvy as an acute treatment for adults with
migraine.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 30, 2021 08:35 ET (12:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2023 to Sep 2024